Axsome Therapeutics SWOT analysis: strong growth, pipeline potential lift stock By Investing.com
Axsome Therapeutics SWOT analysis: strong growth, pipeline potential lift stock…
164,490$
1,33%
Echtzeit-Aktienkurs Axsome Therapeutics Inc.
Bid:
Ask:
Nachrichten zur Axsome Therapeutics Inc. Aktie
Axsome Therapeutics: 80 % Umsatzwachstum durch neue Therapien des zentralen Nervensystems
Biopharmazeutische Unternehmen konzentrieren sich meist auf die Behandlung schwerwiegender und oft unzureichend behandelter Erkrankungen. Entsprechend groß ist der Bedarf an…
Axsome Therapeutics Aktie: Positive Überraschung gelungen!
Die Axsome Therapeutics Aktie verzeichnet zum Ende des Jahres 2024 eine bemerkenswerte Marktpräsenz mit einer Marktkapitalisierung von 4,5 Milliarden Euro.…
Is It Too Late to Buy Viking Therapeutics Stock?
Equity markets have performed well in 2024, but their showing pales next to that of Viking Therapeutics (NASDAQ: VKTX), a…
Axsome Therapeutics (AXSM) Q3 2024 Earnings Call Transcript
AXSM earnings call for the period ending September 30, 2024.…
Axsome Therapeutics, Inc. 2024 Q3 - Results - Earnings Call Presentation
…
Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024
NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and…
Axsome Therapeutics Aktie: FDA akzeptiert erneuten Zulassungsantrag
Die Axsome Therapeutics Aktie zeigt sich stabil bei 80,25 EUR, während das Unternehmen einen wichtigen regulatorischen Meilenstein erreicht hat. Die…
Axsome Therapeutics reaches agreement to dismiss patent litigation with Sandoz
…
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Aug. 10, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…
Axsome Therapeutics (AXSM) Q2 2024 Earnings Call Transcript
AXSM earnings call for the period ending June 30, 2024.…
Axsome Therapeutics, Inc. (AXSM) Q2 2024 Earnings Call Transcript
…
Axsome Therapeutics Q2 2024 Earnings Preview
…
Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and…
5 Biggest Pharmaceutical ETFs in 2024
The global pharmaceutical market reached a total value of US$1.6 trillion in 2023, according to Statista, up significantly from the…
Axsome Therapeutics (AXSM) Q1 2024 Earnings Call Transcript
AXSM earnings call for the period ending March 31, 2024.…
Axsome Therapeutics, Inc. (AXSM) Q1 2024 Earnings Call Transcript
…
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, April 12, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and…
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
AXS-12 statistically significantly reduced cataplexy attacks compared to placebo (p=0.018, primary endpoint)…